BNIP3 as a potential biomarker for the identification of prognosis and diagnosis in solid tumours
Qin Yu,Wenhao Fu,Yutang Fu,Wenjing Ye,Huiqiong Yan,Zecheng Yu,Ruirui Li,Yili Cai,Yuxin Chen,Lingyun Wang,Xianqiao Wei,Yangkun Chen,Yuheng Zhang,Huazhong Ying,Furong Tang,Fangwei Dai,Wei Han
DOI: https://doi.org/10.1186/s12943-023-01808-9
2023-08-30
Abstract:Background: Traditional radiotherapy and chemotherapy have been intensively studied for their role in the treatment of tumours. However, these therapies often cause side effects for patients, which calls for the development of novel treatment options for tumours. B-cell lymphoma-2 (Bcl-2)/adenovirus E1B 19 kDa-interacting protein 3 (BNIP3) reportedly apoptosis-inducing effects in tumour cells and is associated with the progression and treatment of multiple tumours. Nevertheless, little is known about its potential role in tumour diagnosis and targeted therapy. Findings: The results of the study demonstrated that the interaction of BNIP3 with HDAC1 may affect the progression of breast invasive cancer (BRCA), sarcoma (SARC), kidney renal clear cell carcinoma (KIRC), and low-grade glioma (LGG). BNIP3 seemed to exert its effects in BRCA and SARC primarily through gene silencing and integrator complex, and in KIRC and LGG, mainly by affecting olfactory function, suggesting that targeted therapy can be developed based on the above signalling pathway and downstream molecules. Interpretation: BNIP3 has emerged as a promising therapeutic and diagnostic target for BRCA, SARC, KIRC, and LGG, providing new insights into tumour molecular therapies in the clinic.